Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers

Table 3 Correlations of plasma LCN2 and CSF biomarkers in dementia groups

	t-tau	p-tau	Abeta42	Abeta40
AD
rho	−0.098	−0.112	0.182	0.070
95% CI	−0.332 to 0.147	−0.344 to 0.134	−0.406 to 0.062	−0.193 to 0.323
p-value	0.420	0.358	0.131	0.592
VaD
rho	0.281	−0.141	−0.030
95% CI	−0.114 to 0.600	−0.517 to 0.280	−0.438 to 0.389	n.a.
p-value	0.147	0.501	0.891
LBD
rho	0.078	−0.119	−0.296
95% CI	−0.233 to 0.374	−0.444 to 0.233	−0.560 to 0.022	n.a.
p-value	0.617	0.495	0.060
CJD
rho	−0.028	−0.071	0.105
95% CI	−0.247 to 0.103	−0.372 to 0.243	−0.168 to 0.362	n.a.
p-value	0.798	0.651	0.439
FTD
rho	−0.041	−0.148	0.031
95% CI	(−0.411 to 0.341)	−0.54 to 0.316	−0.388 to 0.439	n.a.
p-value	0.832	0.522	0.887

Correlation coefficient (rho), 95% confidence interval (95% CI), and p-values from non-parametric spearman correlations are indicated
AD Alzheimer’s disease, VaD Vascular dementia, LBD Lewy body diseases, CJD Creutzfeldt-Jakob disease, FTD Fronto-temporal dementia, t-Tau CSF Total tau protein, p-tau CSF Phosphorylated tau protein, Abeta42 CSF beta-amyloid 1-42, Abeta40 CSF beta-amyloid 1-40

ISSN: 1758-9193